Cargando…

Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area

Although induction chemotherapy (IC) combined with intensity-modulated radiotherapy (IMRT) plus concurrent chemotherapy (CC) is the new standard treatment option in locoregionally advanced nasopharyngeal carcinoma (NPC), many patients fail to receive CC. The aim of this study was to investigate long...

Descripción completa

Detalles Bibliográficos
Autores principales: Fangzheng, Wang, Chuner, Jiang, Haiyan, Qin, Quanquan, Sun, Zhimin, Ye, Tongxin, Liu, Jiping, Liu, Peng, Wu, Kaiyuan, Shi, Zhenfu, Fu, Yangming, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940191/
https://www.ncbi.nlm.nih.gov/pubmed/31861031
http://dx.doi.org/10.1097/MD.0000000000018484
_version_ 1783484316067561472
author Fangzheng, Wang
Chuner, Jiang
Haiyan, Qin
Quanquan, Sun
Zhimin, Ye
Tongxin, Liu
Jiping, Liu
Peng, Wu
Kaiyuan, Shi
Zhenfu, Fu
Yangming, Jiang
author_facet Fangzheng, Wang
Chuner, Jiang
Haiyan, Qin
Quanquan, Sun
Zhimin, Ye
Tongxin, Liu
Jiping, Liu
Peng, Wu
Kaiyuan, Shi
Zhenfu, Fu
Yangming, Jiang
author_sort Fangzheng, Wang
collection PubMed
description Although induction chemotherapy (IC) combined with intensity-modulated radiotherapy (IMRT) plus concurrent chemotherapy (CC) is the new standard treatment option in locoregionally advanced nasopharyngeal carcinoma (NPC), many patients fail to receive CC. The aim of this study was to investigate long-term survival outcomes and toxicities in these patients who are treated with IC before IMRT without CC. We retrospectively reviewed 332 untreated, newly diagnosed locoregionally advanced NPC patients who received IC before IMRT alone at our institution from May 2008 through April 2014. The IC was administered every 3 weeks for 1 to 4 cycles. Acute and late radiation-related toxicities were graded according to the acute and late radiation morbidity scoring criteria of the radiation therapy oncology group. The accumulated survival was calculated according to the Kaplan–Meier method. The log-rank test was used to compare the difference in survival. With a median follow-up duration of 65 months (range: 8–110 months), the 5-year estimated locoregional relapse-free survival, distant metastasis-free survival, progression-free survival (PFS), and overall survival rates were 93.4%, 91.7%, 85.8%, and 82.5%, respectively. Older age and advanced T stage were adverse prognostic factors for overall survival, and the absence of comorbidity was a favorable prognostic factor for PFS. However, acceptable acute complications were observed in these patients. IC combined with IMRT alone provides promising long-term survival outcomes with manageable toxicities. Therefore, the omission of CC from the standard treatment did not affect survival outcomes.
format Online
Article
Text
id pubmed-6940191
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-69401912020-01-31 Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area Fangzheng, Wang Chuner, Jiang Haiyan, Qin Quanquan, Sun Zhimin, Ye Tongxin, Liu Jiping, Liu Peng, Wu Kaiyuan, Shi Zhenfu, Fu Yangming, Jiang Medicine (Baltimore) 5700 Although induction chemotherapy (IC) combined with intensity-modulated radiotherapy (IMRT) plus concurrent chemotherapy (CC) is the new standard treatment option in locoregionally advanced nasopharyngeal carcinoma (NPC), many patients fail to receive CC. The aim of this study was to investigate long-term survival outcomes and toxicities in these patients who are treated with IC before IMRT without CC. We retrospectively reviewed 332 untreated, newly diagnosed locoregionally advanced NPC patients who received IC before IMRT alone at our institution from May 2008 through April 2014. The IC was administered every 3 weeks for 1 to 4 cycles. Acute and late radiation-related toxicities were graded according to the acute and late radiation morbidity scoring criteria of the radiation therapy oncology group. The accumulated survival was calculated according to the Kaplan–Meier method. The log-rank test was used to compare the difference in survival. With a median follow-up duration of 65 months (range: 8–110 months), the 5-year estimated locoregional relapse-free survival, distant metastasis-free survival, progression-free survival (PFS), and overall survival rates were 93.4%, 91.7%, 85.8%, and 82.5%, respectively. Older age and advanced T stage were adverse prognostic factors for overall survival, and the absence of comorbidity was a favorable prognostic factor for PFS. However, acceptable acute complications were observed in these patients. IC combined with IMRT alone provides promising long-term survival outcomes with manageable toxicities. Therefore, the omission of CC from the standard treatment did not affect survival outcomes. Wolters Kluwer Health 2019-12-20 /pmc/articles/PMC6940191/ /pubmed/31861031 http://dx.doi.org/10.1097/MD.0000000000018484 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 5700
Fangzheng, Wang
Chuner, Jiang
Haiyan, Qin
Quanquan, Sun
Zhimin, Ye
Tongxin, Liu
Jiping, Liu
Peng, Wu
Kaiyuan, Shi
Zhenfu, Fu
Yangming, Jiang
Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
title Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
title_full Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
title_fullStr Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
title_full_unstemmed Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
title_short Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
title_sort survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: single-center experience from an endemic area
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940191/
https://www.ncbi.nlm.nih.gov/pubmed/31861031
http://dx.doi.org/10.1097/MD.0000000000018484
work_keys_str_mv AT fangzhengwang survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea
AT chunerjiang survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea
AT haiyanqin survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea
AT quanquansun survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea
AT zhiminye survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea
AT tongxinliu survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea
AT jipingliu survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea
AT pengwu survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea
AT kaiyuanshi survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea
AT zhenfufu survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea
AT yangmingjiang survivalwithoutconcurrentchemotherapyforlocoregionallyadvancednasopharyngealcarcinomatreatedwithinductionchemotherapyplusintensitymodulatedradiotherapysinglecenterexperiencefromanendemicarea